Up next

Autoplay

NCCN Guidelines for HR+ HER2 Metastatic Breast Cancer

3 Views • 07/03/23
Share
Embed
administrator
administrator
Subscribers
0

Debu Tripathy, MD, and Hatem Soliman, MD, reflect on the NCCN guideline criteria and patient factors that play into decision making for frontline therapy in hormone receptor–positive metastatic breast cancer.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay